Progress toward the development of a genetically engineered attenuated hepatitis A virus vaccine

Journal of Virology

Volumn 70, Issue 11, 1996, Pages 7948-7957

  Funkhouser, Ann W ^a   Raychaudhuri, Gopa ^a   Purcell, Robert H ^a   Govindarajan, Sugantha ^b   Elkins, Randall ^c   Emerson, Suzanne U ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b RANCHO LOS AMIGOS NATIONAL REHABILITATION CENTER   (United States)

^c Div of Neurbio Genet and Behav   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; HEPATITIS A VACCINE; LIVE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CERCOPITHECIDAE; CHIMERA; CONTROLLED STUDY; GENETIC ENGINEERING; HEPATITIS A; HEPATITIS A VIRUS; NONHUMAN; OPEN READING FRAME; PRIMATE; PRIORITY JOURNAL; VACCINE PRODUCTION; VIRUS ATTENUATION; VIRUS CULTURE; VIRUS EXCRETION; VIRUS GENOME; VIRUS MUTATION; VIRUS VIRULENCE;

EID: 0029839490     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.11.7948-7957.1996     Document Type: Article

References (39)

1. Andre, F. E., A. Hepburn, and E. D'Hondt. 1990. Inactivated candidate vaccines for hepatitis A. Prog. Med. Virol. 37:72-95.
2. Brown, E. A., S. P. Day, R. W. Jansen, and S. M. Lemon. 1991. The 5′ nontranslated region of hepatitis A virus RNA: secondary structure and elements required for translation in vitro. J. Virol. 65:5828-5838.
3. Brown, E. A., A. J. Zajac, and S. M. Lemon. 1994. In vitro characterization of an internal ribosome entry site (1RES) present within the 5′ nontranslated region of hepatitis A virus RNA: comparison with the 1RES of encephalomyocarditis virus. J. Virol. 68:1066-1074.
4. Centers for Disease Control. 1990. Protection against viral hepatitis. Recommendations of the Immunization Practices Advisory Committee (ACIP). Morbid. Mortal. Weekly Rep. 39:1-26.
5. Cohen, J. I., B. Rosenblum, S. M. Feinstone, J. Ticehurst, and R. H. Purcell. 1989. Attenuation and cell culture adaptation of hepatitis A virus (HAV): a genetic analysis with HAV cDNA. J. Virol. 63:5364-5370.
6. Cohen, J. I., B. Rosenblum, J. R. Ticehurst, R. J. Daemer, S. M, Feinstone, and R. H. Purcell. 1987. Complete nucleotide sequence of an attenuated hepatitis A virus: comparison with wild-type virus. Proc. Natl. Acad. Sci. USA 84:2497-2501.
7. Cohen, J. I., J. R. Ticehurst, S. M. Feinstone, B. Rosenblum, and R. H. Purcell. 1987. Hepatitis A virus cDNA and its RNA transcripts arc infectious in cell culture. J. Virol. 61:3035-3039.
8. Cohen, J. I., J. R. Ticehurst, R. H. Purcell, A. Buckler-White, and B. M. Baroudy. 1987. Complete nucleotide sequence of wild-type hepatitis A virus: comparison with different strains of hepatitis A virus and other picornaviruses. J. Virol. 61:50-59.
9. Cui, T., and A. G. Porter. 1995. Localization of binding site for encephalomyocarditis virus RNA polymerase in the 3′-noncoding region of the viral RNA. Nucleic Acids Res. 23:377-382.
10. Daemer, R. J., S. M. Feinstone, I. D. Gust, and R. H. Purcell. 1981. Propagation of human hepatitis A virus in African green monkey kidney cell culture: primary isolation and serial passage. Infect. Immun. 32:388-393.
11. Day, S. P., P. Murphy, E. A. Brown, and S. M. Lemon. 1992. Mutations within the 5′ nontranslated region of hepatitis A virus RNA which enhance replication in BS-C-I cells. J. Virol. 66:6533-6540.
12. D'Hondt, E. Unpublished data.
13. Dienstag, J. L., H. Popper, and R. H. Purcell. 1976. The pathology of viral hepatitis types A and B in chimpanzees. Am. J. Pathol. 85:131-148.
14. Emerson, S. U., Y. K. Huang, and R. H. Purcell. 1993. 2B and 2C mutations are pivotal but mutations throughout the genome of HAV contribute to adaptation to cell culture. Virology 194:475-480.
15. Emerson, S. U., M. Lewis, S. Govindarajan, M. Shapiro, T. Moskal, and R. H. Purcell. 1992. cDNA clone of hepatitis A virus encoding a virulent virus: induction of viral hepatitis by direct nucleic acid transfection of marmosets. J, Virol. 66:6649-6654.
16. Emerson, S. U., C. MeRill, B. Rosenblum, S. Feinslone, and R. H. Purcell. 1991. Mutations responsible for adaptation of hepatitis A virus to efficient growth in cell culture. J. Virol. 65:4882-4886.
17. Funkhouser, A. W. Unpublished data.
18. Funkhouser, A. W., R. H. Purcell, E. D'Hondt, and S. U. Emerson. 1994. Attenuated hepatitis A virus: genetic determinants of adaptation to growth in MRC-5 cells. J. Virol. 68:148-157.
19. Glass, M. J., and D. F. Summers. 1992. A cis-acting element within the hepatitis A virus 5′-non-coding region required for in vitro translation. Virus Res. 26:15-31.
20. Haller, A. A., J. H. C. Nguyen, and B. L. Semler. 1993. Minimum internal ribosome entry site required for poliovirus infectivity. J. Virol. 67:7461-7471.
21. Haller, A. A., S. R. Stewart, and B. L. Semler. 1996. Attenuation stem-loop lesions in the 5′ noncoding region of poliovirus RNA: neuronal cell-specific translation defects. J. Virol. 70:1467-1474.
22. Harmon, S. A., O. C. Richards, D. F. Summers, and E. Ehrenfeld. 1991. The 5′-terminal nucleotides of hepatitis A virus RNA, hut not poliovirus RNA, are required for infectivity. J. Virol. 65:2757-2760.
23. Hellen, C. U., and E. Wimmer. 1995. Translation of encephalomyocarditis virus RNA by internal ribosome entry. Curr. Top. Microbiol. Immunol. 203:31-63.
24. Jansen, R. W., J. E. Newbold, and S. M. Lemon. 1988. Complete nucleotide sequence of a cell culture-adapted variant of hepatitis A virus: comparison with wild-type virus with restricted capacity for in vitro replication. Virology 163:299-307.
25. Karron, R. A., R. J. Daemer, J. R. Ticehurst, E. D'Hondt, H. Popper, K. Mihalik, S. M. Feinstone, and R. H. Purcell. 1988. Studies of prototype live hepatitis A virus vaccines in primate models. J. Infect. Dis. 157:338-345.
26. Krawczynski, K., D. W. Bradley, B. L. Murphy, J. W. Ebert, T. E. Doto, A. Nowoslawski, W. Duermeyer, and J. E. Maynard. 1981. Pathogenetic aspects of hepatitis A infection in enterally inoculated marmosets. Am. J. Clin. Pathol. 76:698-706.
27. pro) binds specifically to the 5′-noncoding region of the viral RNA. J. Biol. Chem. 268:25735-25739.
28. Midthun, K., E. Ellerbeck, K. Gershwin, G. Calandra, D, Krah, M. Mc-Caughtry, D. Nalin, and P. Provost. 1991. Safety and immunogenicity of a live attenuated hepatitis A virus vaccine in seronegative volunteers. J. Infect. Dis. 163:735-739.
29. Nalin, D. R., B. J. Kuter, L. Brown, C. Patterson, G. B. Calandra, A. Werzberger, D. Shouval, E. Ellerbeck, S. Block, R. Bishop, B. Wiens, S. W. Schwartz, J. A. Lewis, R. D. Sitrin, P. J. Provost, W. J. Miller, and J. L. Ryan. 1993. Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview. J. Hepatol. 18(Suppl. 2):S51-S55.
30. Provost, P. J., R. P. Bishop, R. J. Gerety, M. R. Hilleman, W. J. McAleer, E. M. Scolnick, and C. E. Stevens. 1986. New findings in live, attenuated hepatitis A vaccine development. J. Med. Virol. 20:165-175.
31. Purcell, R. H. Unpublished data.
32. Ran, L., D. Wang, Q. Duan, T. Yan, Q. Liu, Y. Luo, D. Yang, D. Yang, Z. Xiao, Q. Xie, W. Li, and S. Luo. 1993. Safety and immunogenicity of live attenuated hepatitis A virus vaecine (H2) in humans. Chin. Med. J. 106:604-607.
33. Schulteiss, T., Y. Y. Kusov, and V. Gauss-Muller. 1994. Proteinase 3C of hepatitis A virus (HAV) cleaves HAV polyprotein P2-P3 at all sites including VP1/2A and 2A/2B. Virology 198:275-281.
34. Schultz, D. E., M. Honda, L. E. Whetter, K. L. McKnight, and S. M. Lemon. 1996. Mutations within the 5′ nontranslated RNA of cell culture-adapted hepatitis A virus which enhance cap-independent translation in cultured African green monkey kidney cells. J. Virol. 70:1041-1049.
35. Shaffer, D. R., E. A. Brown, and S. M. Lemon. 1994. Large deletion mutations involving the first pyrimidine-rich tract of the 5′ nontranslated RNA of human hepatitis A virus define two adjacent domains associated with distinct replication phenotypes. J. Virol. 68:5568-5578.
36. Shapiro, C. N., P. J. Coleman, G. M. McQuillan, M. J. Alter, and H. S. Margolis. 1992. Epidemiology of hepatitis A: seroepidemiology and risk groups in the USA. Vaccine 10(Suppl. 1):S59-S62.
37. Sjogren, M. H., R. H. Purcell, K. McKee, L. Binn, P. Macarthy, J. Ticehurst, S. Feinstone, J. Caudill, A. See, C. Hoke, W. Bancroft, and E. D'Hondt. 1992. Clinical and laboratory observations following oral or intramuscular administration of a live attenuated hepatitis A vaccine candidate. Vaccine 10 (Suppl. 1):S135-S137.
38. Vallbracht, A., K. Maier, Y. Stierhof, K. H. Wiedmann, B. Flehmig, and B. Fleischer. 1989. Liver-derived cytotoxic T cells in hepatitis A virus infection. J. Infect. Dis. 160:209-217.
39. Van Damme, P., S. Thoelen, M. Cramm, K. DeGroote, A. Safary, and A. Meheus. 1994. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity. and long-term antibody persistence. J. Med. Virol. 44:446-451.